Current societal guidelines advise differing dosing strategies when it comes to statin usage. The European Society of Cardiology/European Atherosclerosis Society recommends targeting a low-density lipoprotein cholesterol (LDL-C) level less than 70 mg/dL or a 50% LDL-C reduction in very high risk patients while the American College of Cardiology/American Heart Association task force advises high intensity […]
Category: Ischemic heart disease
COURAGE at 15 years
Although PCI improves morbidity and mortality in the context of an acute coronary syndrome, the benefit of PCI in the setting of stable ischemic heart disease appears limited to symptom relief. This was best demonstrated by the COURAGE trial that randomized 2287 patients with stable angina to either intensive medical therapy alone or medical therapy […]
Ranolazine ineffective as antianginal following incomplete revascularization
Ranolazine is a novel anti-anginal medication that operates via late sodium channel blockade, reducing intracellular calcium during ischemia. Prior studies suggest ranolazine is effective in reducing the symptoms of angina among patients with ischemic heart disease. Although revascularization is often used to address symptoms, incomplete revascularization with residual ischemic symptoms is common. In the current […]